Agalimmune has gone from strength to strength since relocating its cancer research and development business to Discovery Park from a leading science park in Cambridge.
The company was launched in 2013 to explore the treatment potential of a new technology, discovered in the United States, to target and destroy cancer cells. It initially leased a laboratory through its parent company, Loxbridge Research at Granta Park but decided to search elsewhere after becoming disillusioned with the lack of collaboration opportunities between businesses on site.
Within three months of being established at Discovery Park, the company made the equivalent of a year’s progress at is previous base. The company, which has 2,500 square feet of offices and laboratory space, is now a subsidiary of Israel-based BioLineRx, which acquired Agalimmune to expand its immuno-oncology drug pipeline.
The company currently has six full time staff bringing in extra staff when needed, using the skills, facilities and expertise of a number of other tenants based at Discovery Park.
Mike Westby, former Chief Executive for Agalimmune, now at the helm of sister company, Centauri Therapeutics, said:
“As a small company Agalimmune were looking for a place with competitive rates, a place with a skilled workforce or potential workforce that we could identify and recruit.
“What we saw at Discovery Park was not only people trained to work in this space who we could access, but also a lot of adjacent companies who had the skills and facilities we could work with in order to establish the business.
So for us, Discovery Park came by far to be the best location to do our business and we worked together with the site management team to build a proposal for a new laboratory that went to the Regional Growth Fund in East Kent.
“We moved onto site in 2014 after our application was approved, using the money to ready the laboratory and buy the necessary equipment to be able to start work.
Within the first three months of being established here Agalimmune made probably the equivalent of one year’s progress of what was happening before, turning an idea into a chemical candidate, which we are able to prepare for clinical testing.”